OVX > OVX/ADX rats. Thus, PXR may be upstream of TSPO, involved in neurosteroidogenesis of 3α,5α-THP in the brain for plasticity. This novel finding of a liver factor involved in behavioral/neural plasticity substantiates future studies investigating factors known for their prominent actions in the peripheral organs, such as the liver, for modulating brain function and its augmentation. " />
Display options
Cite
Frye CA, Koonce CJ, Walf AA. The pregnane xenobiotic receptor, a prominent liver factor, has actions in the midbrain for neurosteroid synthesis and behavioral/neural plasticity of female rats. Front Syst Neurosci. 2014;8:60doi: 10.3389/fnsys.2014.00060.
Frye, C. A., Koonce, C. J., & Walf, A. A. (2014). The pregnane xenobiotic receptor, a prominent liver factor, has actions in the midbrain for neurosteroid synthesis and behavioral/neural plasticity of female rats. Frontiers in systems neuroscience, 860. https://doi.org/10.3389/fnsys.2014.00060
Frye, Cheryl A, et al. "The pregnane xenobiotic receptor, a prominent liver factor, has actions in the midbrain for neurosteroid synthesis and behavioral/neural plasticity of female rats." Frontiers in systems neuroscience vol. 8 (2014): 60. doi: https://doi.org/10.3389/fnsys.2014.00060
Frye CA, Koonce CJ, Walf AA. The pregnane xenobiotic receptor, a prominent liver factor, has actions in the midbrain for neurosteroid synthesis and behavioral/neural plasticity of female rats. Front Syst Neurosci. 2014 Apr 21;8:60. doi: 10.3389/fnsys.2014.00060. eCollection 2014. PMID: 24795576; PMCID: PMC4001026.
Copy Download .nbib Format: NLM
Share it on

Front Syst Neurosci. 2014 Apr 21;8:60. doi: 10.3389/fnsys.2014.00060. eCollection 2014.

The pregnane xenobiotic receptor, a prominent liver factor, has actions in the midbrain for neurosteroid synthesis and behavioral/neural plasticity of female rats.

Frontiers in systems neuroscience

Cheryl A Frye, Carolyn J Koonce, Alicia A Walf

Affiliations

  1. Department of Psychology, The University at Albany-SUNY Albany, NY, USA ; Department of Biological Sciences, The University at Albany-SUNY Albany, NY, USA ; The Center for Neuroscience Research, The University at Albany-SUNY Albany, NY, USA ; The Center for Life Sciences Research, The University at Albany-SUNY Albany, NY, USA ; Department of Chemistry and Biochemistry, The University of Alaska-Fairbanks Fairbanks, AK, USA ; Institute of Arctic Biology, The University of Alaska-Fairbanks Fairbanks, AK, USA ; IDeA Network of Biomedical Excellence (INBRE), The University of Alaska-Fairbanks Fairbanks, AK, USA.
  2. Department of Psychology, The University at Albany-SUNY Albany, NY, USA ; Institute of Arctic Biology, The University of Alaska-Fairbanks Fairbanks, AK, USA ; IDeA Network of Biomedical Excellence (INBRE), The University of Alaska-Fairbanks Fairbanks, AK, USA.

PMID: 24795576 PMCID: PMC4001026 DOI: 10.3389/fnsys.2014.00060

Abstract

A novel factor of interest for growth/plasticity in the brain is pregnane xenobiotic receptor (PXR). PXR is a liver factor known for its role in xenobiotic clearance and cholesterol metabolism. It is expressed in the brain, suggesting a potential role for plasticity, particularly involving cholesterol-based steroids and neurosteroids. Mating induces synthesis of neurosteroids in the midbrain Ventral Tegmental Area (VTA) of female rodents, as well as other "plastic" regions of the brain, including the hippocampus, that may be involved in the consolidation of the mating experience. Reducing PXR in the VTA attenuates mating-induced biosynthesis of the neurosteroid, 5α-pregnan-3α-ol-20-one (3α,5α-THP). The 18 kDA translocator protein (TSPO) is one rate-limiting factor for 3α,5α-THP neurosteroidogenesis. The hypothesis tested was that PXR is an upstream factor of TSPO for neurosteroidogenesis of 3α,5α-THP in the VTA for lordosis, independent of peripheral glands. First, proestrous rats were administered a TSPO blocker (PK11195) and/or 3α,5α-THP following infusions of PXR antisense oligonucleotides (AS-ODNs) or vehicle to the VTA. Inhibiting TSPO with PK11195 reduced 3α,5α-THP levels in the midbrain and lordosis, an effect that could be reversed with 3α,5α-THP administration, but not AS-ODN+3α,5α-THP. Second, proestrous, ovariectomized (OVX), or ovariectomized/adrenalectomized (OVX/ADX) rats were infused with a TSPO enhancer (FGIN 1-27) subsequent to AS-ODNs or vehicle to the VTA. PXR AS-ODNs blocked actions of FGIN 1-27 for lordosis and 3α,5α-THP levels among proestrous > OVX > OVX/ADX rats. Thus, PXR may be upstream of TSPO, involved in neurosteroidogenesis of 3α,5α-THP in the brain for plasticity. This novel finding of a liver factor involved in behavioral/neural plasticity substantiates future studies investigating factors known for their prominent actions in the peripheral organs, such as the liver, for modulating brain function and its augmentation.

Keywords: allopregnanolone; cognition; midbrain ventral tegmental area; progesterone; reproduction

References

  1. Trends Pharmacol Sci. 2006 Aug;27(8):402-9 - PubMed
  2. Proc Natl Acad Sci U S A. 1991 May 15;88(10):4553-7 - PubMed
  3. Psychoneuroendocrinology. 2009 Dec;34 Suppl 1:S143-61 - PubMed
  4. Horm Behav. 2001 Sep;40(2):226-33 - PubMed
  5. Psychopharmacology (Berl). 2000 Jul;151(1):64-71 - PubMed
  6. Mol Endocrinol. 2002 Jun;16(6):1378-85 - PubMed
  7. J Neurosci. 2010 Sep 8;30(36):11896-901 - PubMed
  8. Reproduction. 2009 Jan;137(1):119-28 - PubMed
  9. Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18736-41 - PubMed
  10. Mol Pharmacol. 2004 Sep;66(3):413-9 - PubMed
  11. J Neuroendocrinol. 2011 Nov;23(11):961-73 - PubMed
  12. Psychopharmacology (Berl). 2005 Mar;178(2-3):174-82 - PubMed
  13. J Neuroendocrinol. 2012 Jan;24(1):102-16 - PubMed
  14. Horm Behav. 2008 Nov;54(5):726-34 - PubMed
  15. Neurochem Res. 2008 Oct;33(10):1990-2007 - PubMed
  16. J Pineal Res. 2005 Jan;38(1):27-34 - PubMed
  17. Climacteric. 2006 Dec;9(6):416-20 - PubMed
  18. J Lipid Res. 2012 Feb;53(2):300-10 - PubMed
  19. Neuroendocrinology. 2006;83(5-6):336-47 - PubMed
  20. Brain Res Brain Res Rev. 2001 Nov;37(1-3):201-22 - PubMed
  21. J Biol Chem. 2001 May 4;276(18):14581-7 - PubMed
  22. Nat Chem Biol. 2013 Feb;9(2):126-33 - PubMed
  23. Psychopharmacology (Berl). 2014 Sep;231(17):3375-90 - PubMed
  24. Expert Opin Drug Metab Toxicol. 2008 Jul;4(7):895-908 - PubMed
  25. Neurochem Int. 2012 May;60(6):616-21 - PubMed
  26. J Neuroendocrinol. 1999 Nov;11(11):839-47 - PubMed
  27. Proc Natl Acad Sci U S A. 2012 May 8;109(19):7493-8 - PubMed
  28. JAMA. 2002 Jul 17;288(3):321-33 - PubMed
  29. Cancer Treat Rev. 2007 Jun;33(4):369-80 - PubMed
  30. Annu Rev Physiol. 2003;65:261-311 - PubMed
  31. PLoS One. 2013;8(1):e53376 - PubMed
  32. Psychopharmacology (Berl). 2014 Sep;231(17):3365-74 - PubMed
  33. Steroids. 2008 Oct;73(9-10):906-13 - PubMed
  34. Endocr Rev. 2002 Oct;23(5):687-702 - PubMed
  35. Mol Pharmacol. 2006 Oct;70(4):1212-9 - PubMed
  36. J Cereb Blood Flow Metab. 2004 Oct;24(10):1160-6 - PubMed
  37. Restor Neurol Neurosci. 1992 Jan 1;4(6):425-7 - PubMed
  38. J Neuroendocrinol. 2005 Sep;17(9):545-52 - PubMed
  39. J Steroid Biochem Mol Biol. 1997 Mar;60(5-6):311-8 - PubMed
  40. J Neurosci. 2002 Dec 15;22(24):10613-20 - PubMed
  41. Brain Res. 1993 Apr 2;607(1-2):333-6 - PubMed
  42. Horm Behav. 2009 Oct;56(4):410-5 - PubMed
  43. Behav Neurosci. 1985 Feb;99(1):151-61 - PubMed
  44. J Endocrinol Invest. 2011 Jul-Aug;34(7):e188-99 - PubMed
  45. Behav Neurosci. 2001 Apr;115(2):384-93 - PubMed
  46. Nat Protoc. 2008;3(6):1101-8 - PubMed
  47. J Neurol Sci. 1999 Dec 1;171(1):24-30 - PubMed
  48. Pharmacol Biochem Behav. 2013 Jan;103(3):568-72 - PubMed
  49. Neurobiol Learn Mem. 2007 Sep;88(2):208-16 - PubMed
  50. Behav Brain Res. 2008 Nov 21;193(2):269-76 - PubMed
  51. Pharmacogenomics. 2008 Nov;9(11):1695-709 - PubMed
  52. Nat Rev Endocrinol. 2013 Apr;9(4):241-50 - PubMed
  53. JAMA. 2003 May 28;289(20):2651-62 - PubMed
  54. J Neurosci. 2007 Dec 26;27(52):14470-80 - PubMed
  55. Behav Brain Res. 2005 Feb 28;157(2):343-50 - PubMed
  56. Arterioscler Thromb Vasc Biol. 2008 Mar;28(3):448-54 - PubMed
  57. Brain Res. 1993 Dec 3;629(2):283-92 - PubMed
  58. Horm Behav. 2011 May;59(5):674-80 - PubMed
  59. Neurosci Biobehav Rev. 2010 Mar;34(3):452-67 - PubMed
  60. J Neuroendocrinol. 2008 Apr;20(4):515-25 - PubMed
  61. Reproduction. 2008 Jul;136(1):105-15 - PubMed
  62. J Med Dent Sci. 2004 Mar;51(1):89-98 - PubMed
  63. Int Rev Neurobiol. 2001;46:243-72 - PubMed
  64. J Sex Med. 2013 Jul;10(7):1692-706 - PubMed
  65. Womens Health (Lond). 2007 Nov;3(6):699-710 - PubMed
  66. Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jan 3;48:64-78 - PubMed
  67. Restor Neurol Neurosci. 2004;22(1):19-31 - PubMed
  68. Methods. 2001 Dec;25(4):402-8 - PubMed
  69. Ann N Y Acad Sci. 2003 Dec;1007:298-305 - PubMed
  70. J Biol Chem. 1975 Oct 25;250(20):7997-8003 - PubMed
  71. Physiol Behav. 2005 Apr 13;84(5):799-806 - PubMed
  72. J Cereb Blood Flow Metab. 2002 Oct;22(10):1181-8 - PubMed
  73. Neuroscience. 2006;138(3):1007-14 - PubMed
  74. Neurobiol Learn Mem. 2006 Jul;86(1):35-46 - PubMed
  75. Physiol Behav. 2007 Oct 22;92(3):443-53 - PubMed
  76. Prog Neurobiol. 2014 Feb;113:106-36 - PubMed
  77. J Pharmacol Exp Ther. 2009 Apr;329(1):141-9 - PubMed
  78. Climacteric. 2012 Jun;15(3):256-62 - PubMed
  79. Brain Res Rev. 2008 Mar;57(2):410-20 - PubMed
  80. J Neurochem. 1998 Dec;71(6):2231-8 - PubMed
  81. Front Neurosci. 2012 Jan 19;5:136 - PubMed
  82. Crit Rev Eukaryot Gene Expr. 2002;12(1):53-64 - PubMed
  83. Horm Behav. 2004 Aug;46(2):151-7 - PubMed

Publication Types

Grant support